Herantis Pharma Plc: Managers' transactions – Inveni Life Sciences Fund I Ky
Herantis Pharma Plc Company release, 5 April 2022 at 2:30 p.m. EEST
Herantis Pharma Oyj - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Inveni Life Sciences Fund I Ky
Position: Closely associated person
(X) Legal person
(1):Person Discharging Managerial Responsibilities In Issuer
Name: Aki Prihti
Position: Member of the Board
Issuer: Herantis Pharma Oyj
LEI: 743700W4CQVYAT3WKK38
Notification type: INITIAL NOTIFICATION
Reference number: 12550/4/10
____________________________________________
Transaction date: 2022-04-01
Venue not applicable
Instrument type: SHARE
ISIN: FI4000087861
Nature of the transaction: OTHER
Description: Inveni Life Sciences Fund I Ky is a limited partnership, which distributes the shares in question to its partners without payment.
Transaction details
(1): Volume: 57195 Unit price: 0 N/A
(2): Volume: 28597 Unit price: 0 N/A
(3): Volume: 14299 Unit price: 0 N/A
(4): Volume: 7149 Unit price: 0 N/A
(5): Volume: 7149 Unit price: 0 N/A
(6): Volume: 2574 Unit price: 0 N/A
(7): Volume: 171 Unit price: 0 N/A
Aggregated transactions
(7): Volume: 117134 Volume weighted average price: 0 N/A
____________________________________________
Transaction date: 2022-03-31
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000087861
Nature of the transaction: DISPOSAL
Transaction details
(1): Volume: 411000 Unit price: 1.5 EUR
Aggregated transactions
(1): Volume: 411000 Volume weighted average price: 1.5 EUR
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel.: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: ir@herantis.com
---------------------------------
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400
Company website: www.herantis.com
Herantis Pharma Plc
Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s Disease. Herantis lead product HER-096, is an advanced small and synthetic chemical peptidomimetic version of the active parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the ability to be delivered to the brain via subcutaneous administration.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information, please visit https://www.herantis.com.